RGDV-modified gemcitabine: a nano-medicine capable of prolonging half-life, overcoming resistance and eliminating bone marrow toxicity of gemcitabine
Wenchao Liu1,2, Yujia Mao1,2, Xiaoyi Zhang1,2, Yaonan Wang1,2, Jianhui Wu1,2, Shurui Zhao1,2, Shiqi Peng1,2, Ming Zhao1–3 1Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, B...
Guardado en:
Autores principales: | Liu W, Mao Y, Zhang X, Wang Y, Wu J, Zhao S, Peng S, Zhao M |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d47c9a0f1fb34d9fbf19d8fa3d9804b4 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Overcoming tumor cell chemoresistance using nanoparticles: lysosomes are beneficial for (stearoyl) gemcitabine-incorporated solid lipid nanoparticles
por: Chen Z, et al.
Publicado: (2018) -
Modifying ICCA with Trp-Phe-Phe to Enhance in vivo Activity and Form Nano-Medicine
por: Zhang X, et al.
Publicado: (2020) -
Epigenetic activation of the elongator complex sensitizes gallbladder cancer to gemcitabine therapy
por: Sunwang Xu, et al.
Publicado: (2021) -
Biweekly gemcitabine and paclitaxel in patients with relapsed or metastatic squamous cell carcinoma of the head and neck
por: Ammar Sukari, et al.
Publicado: (2015) -
Thrombotic Microangiopathy Associated with Gemcitabine in Non-Small Cell Lung Cancer: A Case Report
por: Tadahiro Kuribayashi, et al.
Publicado: (2021)